Invited Review

Current Status of Gene Therapy Drugs in Global Market – Updated-2019

Muhammad Irfan-maqsood

Muhammad Irfan-maqsood
VarastehQazal Institute. Email: muhammadirfanmaqsood@gmail.com
Online First: December 30, 2019 | Cite this Article
Irfan-maqsood, M. 2019. Current Status of Gene Therapy Drugs in Global Market – Updated-2019. Journal of Genes and Cells 5(2): 14-21. DOI:10.15562/gnc.68


Gene therapeutic research was considered as the risk based research and arose many ethical issues with the first death caused by gene therapy in 1999. This risky journey remained continued in spite of having several challenges around the world and finally, in 2000 a first success treatment of two children encouraged the scientists and institutes and resulting the approval of first gene therapy drug, Gendicine™ in 2004 by Chinese National Drug Regulatory Authority for the treatment of Cancer. Right after two years, its demand was increased in neighboring countries which boosted the gene therapeutic research worldwide and Glybera™ was produced in late 2012 which got EU approval. Currently, near about 8 gene therapy drugs including Oncorine™, Imlygic™, Zalmoxis™, Strimvelis™, Luxturna™, Kymriah™ and Yescarta™ are in market and tens of under approval for getting license to be available in market for a range of different treatments to make the cure of uncured. Ethical committees world-wide are revising their guidelines for gene therapeutic research and a trust for gene therapy drugs is being developed which is encouraging the more pharma companies to invest in this emerging discipline and creating more hope among public trusting science.

No Supplementary Material available for this article.
Article Views      : 69
PDF Downloads : 0